Research
Molecular
Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.
This suggests potential for new treatments targeting the Y 2 receptor in diabetes.
StrongSupportsmedium confidence
This afforded highly selective long-acting analogs against the Y 2 receptor.
Why this rating
Based on the systematic approach described in the abstract.
Source
Variant screening of PYY <sub>3–36</sub> leads to potent long-acting PYY analogs with superior Y <sub>2</sub> receptor selectivity
Søren Østergaard et al. · Science Translational Medicine · 2025
otherCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →